Cargando…

Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease

BACKGROUND: Patients who develop oligorecurrent disease may be treated with metastasis-directed stereotactic body radiotherapy (SBRT) to defer the start of systemic therapy and delay its potential side effects. We report oncological outcomes and patterns of failure in patients with oligorecurrent di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willmann, Jonas, Vlaskou Badra, Eugenia, Adilovic, Selma, Christ, Sebastian M., Ahmadsei, Maiwand, Mayinger, Michael, Guckenberger, Matthias, Andratschke, Nicolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421088/ https://www.ncbi.nlm.nih.gov/pubmed/36046333 http://dx.doi.org/10.1016/j.ctro.2022.08.008

Ejemplares similares

Continuity and coordination of care in highly selected chronic cancer patients treated with multiple repeat radiation therapy
por: Christ, Sebastian M., et al.
Publicado: (2021)

Quality-of-life and toxicity in cancer patients treated with multiple courses of radiation therapy
por: Ahmadsei, Maiwand, et al.
Publicado: (2022)

Validation and extension of the METSSS score in a metastatic cancer patient cohort after palliative radiotherapy within the last phase of life
por: Christ, Sebastian M., et al.
Publicado: (2022)

Efficacy and safety analysis in metastatic cancer patients treated with multiple courses of repeat radiation therapy
por: Ahmadsei, Maiwand, et al.
Publicado: (2023)

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
por: Schröder, Christina, et al.
Publicado: (2019)

Recognition of and treatment recommendations for oligometastatic disease in multidisciplinary tumor boards
por: Christ, Sebastian M., et al.
Publicado: (2022)

Dosimetric analysis of 17 cardiac Sub-structures, Toxicity, and survival in ultra central lung tumor patients treated with SBRT
por: Ahmadsei, Maiwand, et al.
Publicado: (2023)

Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research
por: Vlaskou Badra, Eugenia, et al.
Publicado: (2021)

Mortality during or shortly after curative-intent radio-(chemo-) therapy over the last decade at a large comprehensive cancer center
por: Christ, Sebastian M., et al.
Publicado: (2023)

Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
por: Rühle, Alexander, et al.
Publicado: (2019)

Dose escalation for stereotactic arrhythmia radioablation of recurrent ventricular tachyarrhythmia - a phase II clinical trial
por: Kovacs, Boldizsar, et al.
Publicado: (2023)

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
por: Berkovic, Patrick, et al.
Publicado: (2020)

Management of multiple brain metastases: a patterns of care survey within the German Society for Radiation Oncology
por: Kraft, Johannes, et al.
Publicado: (2021)

Repeated Courses of Radiosurgery for New Brain Metastases to Defer Whole Brain Radiotherapy: Feasibility and Outcome With Validation of the New Prognostic Metric Brain Metastasis Velocity
por: Fritz, Corinna, et al.
Publicado: (2018)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Single-institution analysis of the prevalence, indications and outcomes of end-of-life radiotherapy
por: Christ, Sebastian M., et al.
Publicado: (2021)

Long-term cancer survivors treated with multiple courses of repeat radiation therapy
por: Christ, Sebastian M., et al.
Publicado: (2021)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
por: Triggiani, Luca, et al.
Publicado: (2017)

Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’
por: Bravo, Isabel
Publicado: (2018)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO)
por: John, Caroline, et al.
Publicado: (2021)

Reply to ‘Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’’
por: Triggiani, Luca, et al.
Publicado: (2018)

Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies
por: Marvaso, Giulia, et al.
Publicado: (2021)

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes
por: Wang, Huan-Huan, et al.
Publicado: (2016)

Definition of stereotactic body radiotherapy: Principles and practice for the treatment of stage I non-small cell lung cancer
por: Guckenberger, M., et al.
Publicado: (2013)

Radiotherapy for glioblastoma patients with poor performance status
por: Schröder, Christina, et al.
Publicado: (2021)

Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience
por: Oehler, Christoph, et al.
Publicado: (2019)

Stereotactic Radiotherapy for the Management of Refractory Ventricular Tachycardia: Promise and Future Directions
por: Jumeau, Raphael, et al.
Publicado: (2020)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study
por: Saltybaeva, Natalia, et al.
Publicado: (2022)

Corrigendum to “Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: Multi-center study” [Phys. Imaging Radiat. Oncol. 22 (2022) 131–136]
por: Saltybaeva, Natalia, et al.
Publicado: (2022)

Prospective randomized clinical studies involving reirradiation: update of a systematic review
por: Nieder, Carsten, et al.
Publicado: (2023)

Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis
por: Mayinger, Michael, et al.
Publicado: (2021)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Prevalence and predictors for 72-h mortality after transfer to acute palliative care unit
por: Christ, Sebastian M., et al.
Publicado: (2022)

Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience
por: Garcia Schüler, Helena Isabel, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
por: Cozzi, Salvatore, et al.
Publicado: (2022)

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
por: Rans, Kato, et al.
Publicado: (2022)

Prospective assessment of stress and health concerns of radiation oncology staff during the COVID-19 pandemic
por: Christ, Sebastian M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ettdigrjka74k5fa9b7t2gqjp7